Last Update 04 Jun 26
LAB: Completed Buyback And Stable Guidance Will Support Future Earnings Profile
Analysts have adjusted their price target on Standard BioTools to $1.55, reflecting updated assumptions that now include a modest positive revenue growth outlook of 13.79%, a slightly higher long term profit margin of 15.57%, a small reduction in the discount rate to 7.83%, and a relatively stable future P/E of about 60x.
What's in the News
- Standard BioTools reaffirmed earnings guidance for fiscal year 2026, continuing to expect revenue in the range of $80 million to $85 million. (Source: Company guidance)
- The company received a notice from Nasdaq on April 20, 2026, stating that it no longer meets the minimum $1.00 bid price requirement for continued listing on the Nasdaq Global Select Market, which triggered an initial 180 day compliance period. (Source: Nasdaq notification)
- The Nasdaq notice does not immediately affect trading of the stock, which continues under the ticker LAB. The company may be eligible for an additional 180 day compliance window if it transfers to the Nasdaq Capital Market and meets other listing standards. (Source: Nasdaq notification)
- Standard BioTools completed its previously announced buyback program, repurchasing a total of 13,603,617 shares for $35.91 million, representing 7.63% of its shares. (Source: Buyback update)
Valuation Changes
- Fair Value: unchanged at $1.55 per share, indicating no adjustment to the overall valuation outcome.
- Discount Rate: reduced slightly from 7.94% to 7.83%, reflecting a modest change in the required rate of return used in the model.
- Revenue Growth: revised from a prior assumption of revenue declining 32.57% to revenue growing 13.79%, representing a major shift in the outlook for future sales trends.
- Net Profit Margin: adjusted slightly higher from 15.52% to 15.57%, implying a small improvement in expected long term profitability.
- Future P/E: kept relatively stable, moving from 59.60x to about 60.0x, indicating only a minor change in the valuation multiple applied to future earnings.
Key Takeaways
- Strategic mergers and partnerships, along with cost synergies, aim to improve profitability and net margins significantly.
- Product integration in proteomics and genomics taps into a large market, while a focus on consumables enhances recurring revenue growth.
- Challenges in revenue growth, macroeconomic uncertainties, and risks associated with mergers and tariffs could impact Standard BioTools' financial stability and operational efficiency.
Catalysts
About Standard BioTools- Provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific.
- The merger with SomaLogic, along with the successful operationalization of $80 million in cost synergies ahead of schedule and an additional $10 million in cost reductions this year, positions Standard BioTools to improve its net margins and profitability.
- The partnership with Illumina and upcoming launch of products integrating proteomics with genomics technology creates a significant opportunity to expand revenue streams, tapping into an expansive billion-dollar market potential in proteomics.
- An anticipated focus on higher-margin consumables is expected to boost overall profitability and contribute to a shift in product mix, potentially driving net margin improvements.
- The strong balance sheet with nearly $300 million in cash provides the capability for strategic acquisitions, supporting long-term revenue growth and market expansion.
- Efforts to diversify and expand the customer base, particularly beyond the top 5 customers in the Lab Services sector, along with a focus on increasing consumable sales, is expected to drive consistent, recurring revenue growth.
Standard BioTools Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Standard BioTools's revenue will remain fairly flat over the next 3 years.
- Analysts are not forecasting that Standard BioTools will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Standard BioTools's profit margin will increase from -58.1% to the average US Life Sciences industry of 15.6% in 3 years.
- If Standard BioTools's profit margin were to converge on the industry average, you could expect earnings to reach $13.5 million (and earnings per share of $0.03) by about June 2029, up from -$50.1 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 60.1x on those 2029 earnings, up from -8.9x today. This future PE is greater than the current PE for the US Life Sciences industry at 37.0x.
- Analysts expect the number of shares outstanding to grow by 2.19% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.83%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The company experienced a 9% year-over-year decline in revenue for the fourth quarter and full year 2024, indicating challenges in maintaining or growing current revenue levels.
- Macroeconomic uncertainties, including potential reductions in NIH funding and cautious spending in academia, are likely to impact revenue, particularly affecting capital equipment purchases in the U.S.
- The company is projecting a 3% decline in organic revenue for 2025 at the midpoint of their range, which suggests they are not anticipating substantial growth in the near term.
- The combination of mergers and acquisitions carries risks, including execution risk, integration challenges, and potential overestimation of cost synergies, which could affect net margins and operational efficiencies.
- The tariff environment adds complexity and potential costs, which could affect gross margins and adjusted EBITDA if new tariffs are absorbed or influence customer demand negatively.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $1.55 for Standard BioTools based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $1.75, and the most bearish reporting a price target of just $1.35.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $86.6 million, earnings will come to $13.5 million, and it would be trading on a PE ratio of 60.1x, assuming you use a discount rate of 7.8%.
- Given the current share price of $1.14, the analyst price target of $1.55 is 26.5% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Standard BioTools?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
